NewsRoom Articles - BioMedWire (BMW)

FridayFeb 27, 2026 10:00 am

UCLA Researchers Develop Method to Fix Fuel Shortages in Cancer Immunotherapy

Many immunotherapies developed to combat cancer fail because the CAR-T cells become exhausted after being starved of oxygen in the tumor environment. A new preclinical study conducted by a team at UCLA has uncovered a method to deliver needed glucose to immune cells in a way that tumor cells cannot hijack. This offers hope of keeping anti-cancer fighter cells active and deadly to both solid and non-solid tumors. The study, whose findings appeared in Cell journal, documents how the researchers found a way to keep the oxygen supply of CAR-T cells intact in a way that cancer cells cannot steal and starve the immune cells. They…

ThursdayFeb 26, 2026 10:00 am

Medicare Advantage Insurers Record Slowing Growth in Member Enrollment

According to data released by the CMS last week, the expansion of people enrolled in Medicare Advantage (MA) plans has decelerated in 2026 to a degree that dwarfs what has been happening in recent years. The CMS data reveals that nearly 35.5 million individuals have so far enrolled for MA programs. This marks a paltry 3% growth of membership compared to last year which saw approximately 34.4 million individuals enroll for MA plans by this time of year. The 3% growth is a far cry from previous years that easily saw annual enrollment tick upwards by 10%. In recent years, the expansion of MA has continued to lose steam as many insurers withdraw from offering MA plans or scale down the number…

WednesdayFeb 25, 2026 9:00 am

Earth Science Tech Inc. (ETST) Accelerates Profitability and Governance Transformation, Signals 40% Net Income Growth Trajectory

ETST reported a third fiscal quarter 2026 revenue of $8.4 million, up 14.1% year-over-year Gross margin expanded to 76.3%, highlighting an improved operating leverage across its portfolio The company announced governance reforms and cost initiatives expected to drive about $1.4 million in annualized savings and over 40% projected net income growth Earth Science Tech (OTC: ETST), a strategic holding company reputed for acquiring and growing high-potential operating businesses, is stepping into a new era of disciplined growth characterized by expanding margins, optimizing cash generation, and a total shift toward a more shareholder-focused public company model. In the company’s third fiscal…

TuesdayFeb 24, 2026 10:00 am

American Science Suffers as Brain Drain Intensifies

The biomedical ecosystem in the U.S. is facing an unprecedented threat as younger researchers opt to work abroad amid the numerous challenges facing innovation within the United States. This brain drain particularly intensified starting last year when a number of policy changes left many with no option but to look for opportunities in other countries. For starters, thousands of grants have been slashed at the National Institutes of Health (NIH) and the National Science Foundation. Research projects at these institutions helped to absorb early career and entry-level scientists with new ideas that they studied using funding from the federal government. Without this vital entry point for young researchers, it is becoming extremely difficult for the country to maintain a…

MondayFeb 23, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC Daresbury Laboratory These updates highlight LIXTE’s overarching mission to blend breakthrough drug development with transformative radiotherapy innovations in the global cancer fight Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments.…

FridayFeb 20, 2026 10:00 am

Cancer Stress Protein Enables Tumors to Evade the Immune System

A study published this week has found that when cancer cells are stressed, they produce a certain protein that helps the cancer to avoid detection by the immune system. This discovery opens an opportunity for developing therapies that target this particular protein in order to make immunotherapy more effective against cancer. The study, which was conducted by a large team led by a group at New York University Langone Health, focused on pancreatic and lung cancer tumors. They studied the ISR (Integrated Stress Response) of the tumors. Tumor cells are constantly stressed because they multiply so fast and often lack all the nutrients they need to support their survival and further…

ThursdayFeb 19, 2026 10:00 am

Expert Calls for Congressional Action on National Health Alert System

For decades, health policymakers have relied on a survey tool to get early awareness of emerging public health threats before they become full-blown crises. The results of those surveys have shaped policy on matters like fortification of foods and the need to conduct public awareness campaigns due to the millions who were found to be unaware that they had high blood pressure. That survey tool is NHANES, or National Health & Nutrition Examination Survey. NHANES has played a pivotal role in shaping public health policy since the 70s, but something happened last year during the longest federal government shutdown that could lead to…

ThursdayFeb 19, 2026 9:00 am

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (“M&As”) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization. Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous system (“CNS”) indications are drawing renewed attention. One such example is Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which recently announced expanded international…

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

TuesdayFeb 17, 2026 9:00 am

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (“CNS”) indications, into focus as strategic assets aligned with current M&A priorities. The company just…